Background: Over the last ten years, a new class of drugs, known as the direct-acting oral
anticoagulants (DOACs), have emerged at the forefront of anticoagulation therapy. Like the …

Although there is controversy about the absolute need for a reversal agent for the new direct
oral anticoagulants (DOACs), the absence of such an agent is a barrier to more widespread …

The direct oral anticoagulants (DOACs) are recommended as the first-choice anticoagulants
for both stroke prevention in patients with non-valvular atrial fibrillation and the treatment …

New guideline recommendations prefer direct oral anticoagulants (DOACs) over warfarin in
DOAC-eligible patients with atrial fibrillation and patients with venous thromboembolism. As …

In the last decade, several direct oral anticoagulants (DOAC; dabigatran, rivaroxaban,
apixaban, edoxaban) have been marketed for prophylaxis and/or treatment of …

Over the past 20 years, there has been a shift from vitamin K antagonists to direct oral
anticoagulants (DOACs), which include the thrombin inhibitor dabigatran and the factor Xa …

Anticoagulation is the cornerstone of prevention and treatment of venous thromboembolism
(VTE) and stroke prevention in patients with atrial fibrillation (AF). However, the mechanisms …

Oral anticoagulants, old and new, are effective therapies for prevention and treatment of
venous thromboembolism and reduction of stroke risk in patients with atrial fibrillation …

Direct oral anticoagulants (DOACs) include dabigatran etexilate, a direct thrombin inhibitor,
and specific inhibitors of activated coagulation factor X (FXa; eg apixaban, betrixaban …

Two specific reversal agents for direct oral anticoagulants (DOACs) have been approved in
the United States: idarucizumab for dabigatran reversal and andexanet alfa for apixaban …